Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-EN Version v2-FR
Language English French
Date Updated 2020-07-15 2020-07-14
Drug Identification Number 02330539 02330539
Brand name TEVA-IRBESARTAN HCTZ TEVA-IRBESARTAN HCTZ
Common or Proper name IRBESARTAN/HCTZ 300/25MG TABS IRBESARTAN/HCTZ 300/25MG TABS
Company Name TEVA CANADA LIMITED TEVA CANADA LIMITED
Ingredients HYDROCHLOROTHIAZIDE IRBESARTAN HYDROCHLOROTHIAZIDE IRBESARTAN
Strength(s) 25MG 300MG 25MG 300MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL ORAL ORAL
Packaging size 100 100
ATC code C09DA C09DA
ATC description ANGIOTENSIN II ANTAGONISTS, COMBINATIONS ANGIOTENSIN II ANTAGONISTS, COMBINATIONS
Reason for shortage Shortage of an inactive ingredient or component. Shortage of an inactive ingredient or component.
Anticipated start date
Actual start date 2020-07-14 2020-07-14
Estimated end date 2020-12-31 2020-12-31
Actual end date 2020-07-14
Shortage status Resolved Anticipated shortage
Company comments Duplicate record created in error Allocation 100% of Teva Market for duration of shortage.
Health Canada comments